Agency Receives Recognition for Flying Start to Partnership
Italian technology service provider DELO Instruments, has been presented with LAUDA Dr R. Wobser GmbH & Co. KG’s award for exceptionally successful new agencies. The celebration took place at the agent’s headquarters in Fizzonasco, south of Milan, where Founder and CEO Claudio Baldi received the award from President & CEO of LAUDA, Dr Gunther Wobser.
“In the last four years, the collaboration between Lauda and DELO has developed beautifully in the area of battery testing for the northern Italian automotive sector,” said Antonio Manconi, Managing Director of Lauda Italia, who is responsible for the direct collaboration with the Italian partner. “By marketing Lauda constant temperature equipment to reputable manufacturers of vehicles and components in Italy, DELO has been able to achieve outstanding results. Our goal is to further expand the business and to support customers in the
automotive industry with optimal temperature control solutions for complex test scenarios.”
“With Lauda Italia S.R.L. and Managing Director Antonio Manconi, we have built up a strong organisation in Italy that has quadrupled our market share to around 40% since it was fi rst founded in 2014,” added Dr Wobser. “DELO Instruments has been a reliable partner at our side since 2018. Thanks to the support of our international agencies, electric mobility is one of Lauda’s fastest-growing areas of business activity. That’s why we would like to thank our new agency, DELO, for a fantastic year in 2021 with this award.”
More information online:
ilmt.co/PL/56xX 59547pr@reply-direct.com
From left: Dino Delbue, Sales Manager DELO, Dr Gunther Wobser, Dr Claudio Baldi, and Antonio Manconi, MD of Lauda Italia. Credit Lauda
New Deals Support Novel Therapies and Improved Assays
HUMAN Celebrates its 50th Anniversary
The development and production site in Magdeburg. Arron Tolley
Aptamer, the developer of Optimer® binders with potential to open avenues of discovery for the life sciences industry, has announced a selection of new contract wins where its proprietary platform technology is being explored by partners to offer new strategies for therapeutics.
These binders, oligonucleotide-based affi nity ligands generated through the in vitro Optimer platform, offer benefi ts of ethical compliance along with ability to pursue optimised targets via 3 parallel discovery processes and screening against end-use application conditions.
Group CEO Dr Arron Tolley said: “Following the successful development and proof-of-concept of an Optimer to correct oncogenic splicing errors in Chronic Myelomonocytic Leukaemia (CMML) we have entered the second phase of our collaboration with Cancer Research UK to develop the delivery vehicle portion of the bispecifi c therapeutic Optimer binder for the treatment of CMML and other myeloid malignancies. This second Optimer binder will enable targeted delivery of the therapeutic molecule for improved effi cacy.
“We’ve also signed a new therapeutic deal to develop Optimers to block the activity of naturally occurring antibodies within the body for use as a potential therapy to prevent transplant rejection. The Optimer binders we generate may then support the development of a companion diagnostic panel, in addition to therapeutic use.”
Since the company’s full year results, the Group’s Aptamer Solutions business was said to have seen signifi cant progress with numerous new projects underway.
“We are working with a biomarker services company to develop Optimer binders to support multiplex biomarker assays for mass spectrometry analysis. The Optimer-based assays will deliver increased sensitivity in identifying and analysing neurodegenerative disease biomarkers to improve clinical trial outcomes in drug development,” added Dr Tolley.
“Finally, we’ve also signed a deal with Novavax, a vaccine developer for respiratory diseases, who require Optimers to improve the selectivity and enable multiplex analysis of their QC assays.”
More information online:
ilmt.co/PL/d14R 59549pr@reply-direct.com
Since its foundation in 1972, HUMAN Gesellschaft für Biochemica und Diagnostica GmbH has been developing and marketing comprehensive solutions for in vitro diagnostics (IVD). The portfolio ranges from classical clinical chemistry to innovative molecular diagnostic methods as well as special applications such as assays for autoimmunity testing.
The German medium-sized company has its headquarters in Wiesbaden and its development and production site in Magdeburg. In addition, HUMAN maintains regional sales offi ces in Singapore, China, India, United Arab Emirates, Panama and has local HUMAN representatives in many other countries.
With its approximately 300 employees from over 40 nations, its worldwide service and delivery capacities, and a broad network of long-standing sales partners, HUMAN supports medical laboratories in more than 160 countries.
“HUMAN has grown from a small reagent manufacturer to a global player in in vitro diagnostics,” says Dr Björn Breth, CEO of HUMAN since 2019. “For 50 years now, we have been helping to improve healthcare in many places around the world. With our comprehensive portfolio, we cover a wide range of regional needs, from semi-automated devices to fully automated solutions. Through our logistics and services, we are a recognised partner to numerous governmental and non-governmental organisations (NGOs) in support of medical
care, particularly in crisis areas. We remain committed to Germany as a business location, where we develop and produce the majority of our products.”
At the development and production site in Magdeburg, Germany, scientists work with modern technologies on further developments and innovations with a focus on clinical chemistry, haematology, haemostasis and immunoassays and in compliance with the highest European quality standards.
Sustainability is a particular concern for HUMAN as a responsible and future-oriented company. A certifi ed environmental management system has been established that meets the requirements of the international ISO 14001 standard and the European EMAS directive. In addition, a resource-effi cient orientation is increasingly taking place in terms of energy generation: at its headquarters, for example, HUMAN already covers over 86% of its annual requirements through renewable energy.
Interesting facts about the 50-year history of HUMAN, milestones and product highlights as well as voices and insights of the cooperation partners can be found on its anniversary page.
More information online:
ilmt.co/PL/2PGJ and
ilmt.co/PL/3Xvk 59541pr@reply-direct.com
Project Expansion Designates Target-Based Development Programme
A neuroscience collaboration with Bristol Myers Squibb that has achieved an expansion of portfolio with two additional drug discovery projects and designated a target-based programme for further development, has triggered payments of US$ 26 million to Evotec SE.
Initiated in December 2016 with the goal of identifying disease- modifying treatments the partnership has leveraged Evotec’s precision medicine technologies for modality-agnostic drug discovery and development. A fi rst programme originating from the collaboration, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021, following the successful fi ling of an IND application with the FDA.
Dr Cord Dohrmann, Chief Scientifi c Offi cer of Evotec, said: “We are delighted to see that after six years our neuroscience collaboration with Bristol Myers Squibb continues to be highly productive across its entire value chain. This is a testament to the scientifi c excellence and dedication of the teams at Evotec and Bristol Myers Squibb. We are confi dent that the growing pipeline of promising development candidates will yield transformative therapeutic options for patients living with neurodegenerative conditions.”
More information online:
ilmt.co/PL/1aeP 59523pr@reply-direct.com
To be included in our next issue, send all your News stories to:
heather@intlabmate.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
